Compare INVA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVA | FTRE |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | INVA | FTRE |
|---|---|---|
| Price | $23.47 | $10.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $36.50 | $15.50 |
| AVG Volume (30 Days) | 762.5K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.23 | $3.21 |
| Revenue Next Year | $8.58 | $0.25 |
| P/E Ratio | $15.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.52 | $3.97 |
| 52 Week High | $23.91 | $18.67 |
| Indicator | INVA | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 80.33 | 27.78 |
| Support Level | $22.12 | $9.42 |
| Resistance Level | $23.42 | $15.00 |
| Average True Range (ATR) | 0.73 | 1.33 |
| MACD | 0.30 | -0.70 |
| Stochastic Oscillator | 91.42 | 13.88 |
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.